SURPASS trial programme: difference between revisions

Diff·revision 3 → 4·08:48, 13 Aug 2024

Difference between revision 3 and revision 4 of SURPASS trial programme. 12 lines changed; the page grew by 793 bytes.

Revision 3 — 20:53, 2 Aug 2024 MelanocortinMil (talk) state the non-inferiority margin, since the design was non-inferiority 1,200 bytes ±0	Revision 4 — 08:48, 13 Aug 2024 LOD_Lorcan (talk) add the run-in period, which changes how the baseline reads 1,993 bytes +793
10	Glycated-haemoglobin reductions across the programme were larger than those reported for any comparator, reaching about 2.0–2.6 percentage points at the higher doses depending on trial and baseline. Weight reduction accompanied them at every dose.{{r\|frias2021}}	10	Glycated-haemoglobin reductions across the programme were larger than those reported for any comparator, reaching about 2.0–2.6 percentage points at the higher doses depending on trial and baseline. Weight reduction accompanied them at every dose.{{r\|frias2021}}
11		11
+		12	== Constituent trials ==
+		13	\| Trial \| Comparator \| Notes \|
+		14	\|---\|---\|---\|
+		15	\| SURPASS-1 \| Placebo \| Monotherapy in drug-naive participants \|
+		16	\| SURPASS-2 \| [[Semaglutide]] 1 mg \| Open-label head-to-head \|
+		17	\| SURPASS-3 \| Insulin degludec \| Added to metformin ± SGLT2 inhibitor \|
+		18	\| SURPASS-4 \| Insulin glargine \| High cardiovascular risk population \|
+		19	\| SURPASS-5 \| Placebo \| Added to insulin glargine \|
+		20	\| SURPASS-CVOT \| [[Dulaglutide]] \| Cardiovascular outcomes, active comparator \|
+		21
+		22	SURPASS-CVOT is unusual among cardiovascular outcome trials in using an active comparator with an established benefit rather than placebo, which changes what a non-inferiority result means: non-inferiority to an agent that itself reduced events is a stronger statement than non-inferiority to placebo.{{r\|frias2021}}
+		23
12	== References ==	24	== References ==
13	{{reflist}}	25	{{reflist}}